Table 2 Clinical and treatment characteristics
|
Total n = 111 |
Myocarditis (Group 1) (n = 20) |
No myocarditis (Group 2) (n = 91) | p-value | |
|---|---|---|---|---|
| Fever | 111/11 (100) | 20/20 (100) | 91/91 (100) | NA |
| Adenopathy | 27/91 (30) | 5/15 (33) | 22/76 (29) | 0.762 |
| Respiratory symptoms | 35/97 (36) | 8/16 (50) | 27/81 (33) | 0.257 |
| Gastrointestinal symptoms | 89/107 (83) | 15/18 (83) | 74/89 (83) | 0.999 |
| Cutaneous symptoms | 70/102 (69) | 12/16 (75) | 58/86 (67) | 0.770 |
| Syncope | 1/108 (1) | 0/17 | 1/91 (1) | 0.999 |
| Palpitation | 13/96 (14) | 3/15 (20) | 10/81 (12) | 0.422 |
| Arrhythmias | 7/104 (7) | 3/17 (18) | 4/87 (5) | 0.084 |
| Chest pain | 12/94 (13) | 4/16 (25) | 8/78 (10) | 0.118 |
| Dyspnea | 34/100 (34) | 8/16 (50) | 26/84 (31) | 0.159 |
| NYHA class I | 68/93 (73) | 8/15 (53) | 60/78 (77) | 0.011* |
| class II | 2/93 (2) | 0/15 | 2/78 (3) | |
| class III | 8/93 (9) | 0/15 | 8/78 (10) | |
| class IV | 15/93 (16) | 7/15 (47) | 8/78 (10) | |
| Hospitalization ICU | 87/111 (78) | 15/20 (75) | 72/91 (79) | 0.765 |
| Arrhythmias during hospitalization | 7/86 (8) | 3/14 (21) | 4/72 (6) | 0.082 |
| Respiratory failure | 45/105 (43) | 7/16 (44) | 38/89 (43) | 0.999 |
| Circulation failure | 69/107 (64) | 9/18 (50) | 60/89 (67) | 0.183 |
| Renal failure | 34/104 (33) | 2/17 (12) | 32/87 (37) | 0.051 |
| Treatment | ||||
| Inotropic support | 71/100 (71) | 11/16 (69) | 60/84 (71) | 0.999 |
| Mechanical support | 9/103 (9) | 4/17 (24) | 5/86 (6) | 0.039 |
| Ventilation support | 40/98 (41) | 6/14 (43) | 34/84 (40) | 0.999 |
| Immunosuppressive therapy during hospitalization | 66/90 (73) | 12/16 (75) | 54/74 (73) | 0.999 |
| Corticosteroids | 91/109 (83) | 17/20 (85) | 74/89 (83) | 0.999 |
| IVIG | 98/109 (90) | 17/19 (89) | 81/90 (90) | 0.999 |
| Antiaggregant therapy | 84/106 (79) | 14/18 (78) | 70/88 (80) | 0.999 |
| Anticoagulant therapy | 66/105 (63) | 12/19 (63) | 53/86 (63) | 0.999 |
| Death | 0 | 0 | 0 | NA |